Law360, New York (November 18, 2009) -- A federal appeals court has found that Cell Therapeutics Inc.’s settlement of a qui tam suit should not preclude it from bringing suit seeking contractual indemnification from its reimbursement consultant for damages as part of the government’s investigation over its leukemia treatment Trisonex.
The U.S. Court of Appeals for the Ninth Circuit on Wednesday reversed a lower court’s summary judgment ruling that CTI’s claims against Lash Group Inc. were barred, finding that the...
